Biopharmaceutical Manufacturing, Upstream, Downstream …
Jan 16, 2025 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
Aditum Bio and Leads Biolabs join forces to fight autoimmune …
Nov 7, 2024 · The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new company that will develop a potentially …
Eli Lilly's eczema drug receives FDA approval one year after its ...
Sep 17, 2024 · At the time, a representative from Eli Lilly stated that the company would work closely with the CRO and the FDA to address the agency’s feedback and make the drug …
FDA removes clinical hold on Novavax’s COVID-19-influenza …
Nov 12, 2024 · The U.S. company Novavax announced yesterday that the FDA has removed the clinical hold placed on its COVID-19-influenza combination (CIC) vaccine and the stand-alone …
BridgeBio wins FDA Approval for cardiomyopathy treatment
Nov 26, 2024 · The exact prevalence of ATTR-CM is uncertain but is thought to be higher than previously thought. Estimates have increased from 5 in 100,000 people in 2004 to 35 per …
FDA approves first mesenchymal stromal cell therapy
Dec 19, 2024 · “Steroid-refractory acute graft-versus-host disease can have significant, wide-ranging health consequences, including damage to multiple organs, reduced quality of life and …
Nucleus RadioPharma secures Series A investment from AstraZeneca
Jun 6, 2024 · Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone …
Anticipation mounts as Insmed's bronchiectasis therapy nears …
May 13, 2024 · The therapy has sparked significant anticipation within the medical community ahead of its phase 3 outcomes. A positive outcome from this study could lay the groundwork …
Astellas licenses AviadoBio’s dementia gene therapy candidate
Oct 10, 2024 · “This strategic collaboration will combine our promising gene therapy candidate for FTD-GRN and delivery expertise with Astellas’ global capabilities in development and …
nChroma Bio formed by merging genetic medicine companies
Dec 12, 2024 · Chroma Bio was launched in 2021 with $125 million in seed funding and aimed to take gene editing one step further by editing the epigenome, namely, markers on the genome …